[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20076355L - Dengue serotype 1 attenuert stamme - Google Patents

Dengue serotype 1 attenuert stamme

Info

Publication number
NO20076355L
NO20076355L NO20076355A NO20076355A NO20076355L NO 20076355 L NO20076355 L NO 20076355L NO 20076355 A NO20076355 A NO 20076355A NO 20076355 A NO20076355 A NO 20076355A NO 20076355 L NO20076355 L NO 20076355L
Authority
NO
Norway
Prior art keywords
dengue serotype
attenuated strain
strain
vdv1
dengue
Prior art date
Application number
NO20076355A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Kinney
Claire Huang
Veronique Barban
Jean Lang
Bruno Guy
Original Assignee
Ct S For Disease Control And P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct S For Disease Control And P filed Critical Ct S For Disease Control And P
Publication of NO20076355L publication Critical patent/NO20076355L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO20076355A 2005-06-17 2007-12-12 Dengue serotype 1 attenuert stamme NO20076355L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69124305P 2005-06-17 2005-06-17
PCT/IB2006/001313 WO2006134433A1 (en) 2005-06-17 2006-05-18 Dengue serotype 1 attenuated strain

Publications (1)

Publication Number Publication Date
NO20076355L true NO20076355L (no) 2008-03-11

Family

ID=36933493

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076355A NO20076355L (no) 2005-06-17 2007-12-12 Dengue serotype 1 attenuert stamme

Country Status (16)

Country Link
US (3) US7641907B2 (ko)
EP (1) EP1893637B1 (ko)
JP (1) JP5197362B2 (ko)
KR (2) KR101536612B1 (ko)
CN (1) CN101238144B (ko)
AR (1) AR053913A1 (ko)
AU (1) AU2006257610B2 (ko)
BR (1) BRPI0613328A2 (ko)
CA (1) CA2611934C (ko)
IL (1) IL188041A0 (ko)
MX (1) MX2007015873A (ko)
MY (1) MY144689A (ko)
NO (1) NO20076355L (ko)
TW (1) TWI414605B (ko)
WO (1) WO2006134433A1 (ko)
ZA (1) ZA200710714B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103555669B (zh) 2002-01-15 2017-10-13 赛诺菲巴斯德生物制剂有限责任公司 黄病毒疫苗
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2254594B1 (en) 2008-03-05 2015-06-03 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
WO2011026139A1 (en) 2009-08-31 2011-03-03 Gen-Probe Incorporated Dengue virus assay
MX2015000446A (es) 2012-07-24 2015-03-12 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
US20150196631A1 (en) 2012-07-24 2015-07-16 Sanofi Pasteur Vaccine compositions
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
CA2933472A1 (en) * 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
CA3177572A1 (en) * 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
MX366154B (es) 2013-06-21 2019-06-28 Merck Sharp & Dohme Composiciones de vacuna del virus del dengue y metodos de uso de las mismas.
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
MX2017008342A (es) 2014-12-22 2017-10-24 Merck Sharp & Dohme Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
WO2017090762A1 (ja) * 2015-11-27 2017-06-01 一般財団法人化学及血清療法研究所 デングウイルス弱毒株をバンク化した生ウイルス、及びそれらを抗原とするデングワクチン
US11690903B2 (en) 2017-10-05 2023-07-04 Sanofi Pasteur Compositions for booster vaccination against dengue

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ES2322327T3 (es) * 1999-03-26 2009-06-19 Walter Reed Army Institute Of Research Vacuna multivalente contra el virus del dengue.
AU3844101A (en) * 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
ES2315221T3 (es) * 2000-05-30 2009-04-01 Mahidol University Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea.
EP1358319B1 (en) 2000-09-25 2009-06-17 Polymun Scientific Immunbiologische Forschung GmbH Live influenza vaccine and method of manufacture
ES2523168T3 (es) 2001-05-22 2014-11-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos
SI1554301T1 (sl) * 2002-05-03 2011-01-31 Us Health VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE
JP4537045B2 (ja) * 2003-12-11 2010-09-01 キヤノン株式会社 電子ペーパー、電子ペーパー接続装置、システム、電子ペーパーにおける制御方法及びコンピュータプログラム

Also Published As

Publication number Publication date
TWI414605B (zh) 2013-11-11
MY144689A (en) 2011-10-31
US9169298B2 (en) 2015-10-27
KR20140006119A (ko) 2014-01-15
ZA200710714B (en) 2008-11-26
TW200741002A (en) 2007-11-01
JP2008546382A (ja) 2008-12-25
CA2611934A1 (en) 2006-12-21
US20120083584A1 (en) 2012-04-05
CN101238144B (zh) 2012-09-05
AR053913A1 (es) 2007-05-23
MX2007015873A (es) 2008-04-22
US20100137571A1 (en) 2010-06-03
KR101536612B1 (ko) 2015-07-14
WO2006134433A1 (en) 2006-12-21
EP1893637A1 (en) 2008-03-05
CA2611934C (en) 2015-11-03
KR20080027356A (ko) 2008-03-26
JP5197362B2 (ja) 2013-05-15
CN101238144A (zh) 2008-08-06
EP1893637B1 (en) 2016-01-06
IL188041A0 (en) 2008-03-20
US8067565B2 (en) 2011-11-29
KR101464649B1 (ko) 2014-12-01
US7641907B2 (en) 2010-01-05
AU2006257610A1 (en) 2006-12-21
AU2006257610B2 (en) 2012-11-15
BRPI0613328A2 (pt) 2011-01-04
US20060292172A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
NO20076355L (no) Dengue serotype 1 attenuert stamme
NO20076360L (no) Dengue serotype 2 attenuert stamme
SG159542A1 (en) Compositions against sars-coronavirus and uses thereof
MY156422A (en) Methods and compositions for live attenuated viruses
HK1118563A1 (en) Influenza viruses able to infect canids, uses thereof
NO20090194L (no) Rekombinant viral vaksine
TR201910900T4 (tr) Desferritiyokin polieter analogları.
NO20084850L (no) MGLUR5 modulatorer I
NO20064034L (no) Makrolider og fremgangsmater for a fremstille disse
NO20074885L (no) N-proteinmutanter av porcinreproduktive og andedrettssyndromvirus
DK1965809T3 (da) Præparater til forbedring af sundhedstilstanden i dyrs tarmsystem og dyrs ydeevne omfattende Beta-glucanerne og Alfa-fucaner
SG170751A1 (en) Extractions and methods comprising elder species
CY1114562T1 (el) Υψηλης καθαροτητας μεγαλης κλιμακας παρασκευη στανσοπορφινης
NO20083065L (no) Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstander
WO2011017132A3 (en) Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
NO20082704L (no) Hepatitt C virusvarianter
CL2008000518A1 (es) Composicion de control de plagas que comprende etofenprox y un compuesto desinfectante seleccionado entre flusulfamida, himexazol, simeconazol, y pentiopirad; y metodo de prevencion del dano producido por plagas.
DE602008000315D1 (de) Methode zur Bestimmung des Ursprungs der Zusammensetzung eines Gases, das aus dem thermischen Abbau von Kohlenstoff hervorgegangen ist
WO2007002587A3 (en) Inhibitors of epstein barr virus nuclear antigen 1
WO2010088222A3 (en) A high molecular weight polysaccharide that binds and inhibits virus
DK1926472T3 (da) Stabiliserede og konserverede ketotifenholdige oftalmiske sammensætninger
EA200801297A1 (ru) Способ снижения уровня постпрандиальной глюкозы
NO20091386L (no) Fenyloksyanilinderivater
NO20081235L (no) Benzotiadiazolyfenylalkylaminderivater for anvendelse for behandling av lidelser lindret av monoamin reopptak
NO20074136L (no) Orale sammensetninger for forebygging av UV-skader

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application